| Combination of | |
|---|---|
| Dolutegravir | Integrase strand transfer inhibitor |
| Lamivudine | Nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil | Nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Other names | Tenofovir/lamivudine/dolutegravir (TLD) |
| Routes of administration | By mouth |
| ATC code | |
Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is afixed-dose combinationantiretroviral medication used to treatHIV/AIDS.[1] It is a combination ofdolutegravir,lamivudine, andtenofovir disoproxil.[1] As of 2019[update], it is listed by theWorld Health Organization (WHO) as the first line treatment for adults, withtenofovir/lamivudine/efavirenz as an alternative.[2] It is takenby mouth.[3]
Side effects may includetrouble sleeping,weight gain, and rash.[2][3] While there are concerns that use during pregnancy results in a 0.2% increased risk ofneural tube defects in the baby, this does not rule out its use.[2] Use remains recommended after thefirst trimester.[2] Use is not recommended in those withkidney problems.[3] The combination is a type ofantiretroviral therapy.[2]
It is on theWorld Health Organization's List of Essential Medicines.[4] In some countries it is available as ageneric medication.[5] It is tentatively approved in the United States as of 2019, full approval is pending expiration of the US patents ondolutegravir (Tivicay) andtenofovir disoproxil (Viread).[6][7]
As of 2019, it is listed by theWorld Health Organization (WHO) as the first-line treatment for adults withHIV/AIDS, withtenofovir/lamivudine/efavirenz as an alternative.[2] It may be used in people with both HIV andtuberculosis, however if the person is onrifampicin a larger dose ofdolutegravir is needed.[2]
Side effects may includetrouble sleeping andweight gain.[2] While there are concerns that use during pregnancy results in a 0.2% increased risk ofneural tube defects in the baby, this does not rule out its use.[2] Use remains recommended after thefirst trimester.[2] It should not be used withdofetilide.[3]
In the developing world it costs aboutUS$75 per year.[8] It is considered more cost effective than tenofovir/lamivudine/efavirenz as of 2019.[2]
